Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$163.37 USD

163.37
398,547

-0.85 (-0.52%)

Updated Sep 18, 2024 02:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus

by Zacks Equity Research

Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.

CVS Health's (CVS) Front Store Sales Robust, LTC Suffers

by Zacks Equity Research

CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.

Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.

Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health

by Zacks Equity Research

Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.

Select Medical (SEM) Rides on a Diversified Business Profile

by Zacks Equity Research

Select Medical's (SEM) supremacy in a fragmented market and its affordable healthcare services in each of its business segments bode well for the long haul.

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Allscripts (MDRX) stock on the back of its solid prospects.

    New Strong Buy Stocks for December 23rd

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

    Medtronic (MDT) Gets Canada Nod for Micra AV to Treat AV Block

    by Zacks Equity Research

    With the approval, Medtronic (MDT) aims to strengthen its Cardiac and Vascular Group business globally.

    Why You Should Retain Avanos Medical (AVNS) Stock for Now

    by Zacks Equity Research

    Investor confidence is high on Avanos Medical (AVNS), courtesy of solid prospects.

      Varian (VAR) Inks Deal With Yonsei Cancer Center in Korea

      by Zacks Equity Research

      Varian (VAR) will be coordinating with Yonsei Cancer Center on formulating AI solutions, which are proven to upgrade early detection of cancer.

      Here's Why You Should Hold onto Varian Medical (VAR) Stock Now

      by Zacks Equity Research

      Investor confidence is high on Varian Medical (VAR) stock, courtesy of solid prospects.

      Veeva (VEEV) Vault QMS Gets Picked by Samsung Biologics

      by Zacks Equity Research

      Veeva Systems' (VEEV) Vault Quality Suite gets selected by Samsung Biologics to drive quality process and content management for better visibility across the latter's global processes.

        Should Value Investors Buy DaVita HealthCare (DVA) Stock?

        by Zacks Equity Research

        Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

        Masimo (MASI) Releases Favorable Findings on Pulse Oximetry

        by Zacks Equity Research

        Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.

        Encompass Health (EHC) to Spin Off Unit to Streamline Business

        by Zacks Equity Research

        Encompass Health (EHC) is exploring strategic alternatives to split its home health and hospice business from the original corporate structure to streamline operations.

        DVA vs. CHE: Which Stock Is the Better Value Option?

        by Zacks Equity Research

        DVA vs. CHE: Which Stock Is the Better Value Option?

        Should Value Investors Buy DaVita HealthCare (DVA) Stock?

        by Zacks Equity Research

        Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

        Should Value Investors Choose DaVita (DVA) Stock Now?

        by Zacks Equity Research

        Is DaVita (DVA) a great pick from the value investor's perspective right now? Read on to know more.

        Why DaVita (DVA) Could Be an Impressive Growth Stock

        by Zacks Equity Research

        If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).

        DaVita's (DVA) Shares March Higher, Can It Continue?

        by Zacks Equity Research

        As of late, it has definitely been a great time to be an investor in DaVita (DVA).

        DVA or CHE: Which Is the Better Value Stock Right Now?

        by Zacks Equity Research

        DVA vs. CHE: Which Stock Is the Better Value Option?

        Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

        by Zacks Equity Research

        Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.

          Allscripts' (MDRX) Veradigm Collaborates With HealthVerity

          by Zacks Equity Research

          Allscripts (MDRX) and HealthVerity will be committed toward catering to specific industry needs by helping clients design linked data solutions that are fit-for-purpose.

          Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now

          by Zacks Equity Research

          Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.

          AngioDynamics (ANGO) Shows Solid Results from RAPID Database

          by Zacks Equity Research

          The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.